down arrow

Vivani Medical, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92854B1098
USD
1.41
0.07 (5.22%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.381.43

52 Week

0.911.92
Valuation
Technical
Day's Volume

CASH

104.41 k

Shareholding (Mar 2025)

FII

2.21%

Held by 7 FIIs

DII

95.17%

Held by 3 DIIs

Promoter

0.00%

How big is Vivani Medical, Inc.?

22-Jun-2025

As of Jun 18, Vivani Medical, Inc. has a market capitalization of 68.13 million and reported net sales of 0.00 million with a net profit of -23.75 million over the last four quarters. The balance sheet shows shareholder's funds of 17.61 million and total assets of 41.56 million.

As of Jun 18, Vivani Medical, Inc. has a market capitalization of 68.13 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -23.75 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 17.61 million and total assets amounting to 41.56 million.

Read More

What does Vivani Medical, Inc. do?

22-Jun-2025

Vivani Medical, Inc. develops and markets prosthetic devices aimed at restoring vision for blind individuals, operating in the Pharmaceuticals & Biotechnology sector with a market cap of $68.13 million. The company reported a net profit loss of $6 million as of March 2025.

Overview: <BR>Vivani Medical, Inc. is engaged in developing, manufacturing, and marketing prosthetic devices that restore vision to blind individuals, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 68.13 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -204.31% <BR>Price to Book: 5.86<BR><BR>Contact Details: <BR>Address: 12744 San Fernando Rd Bldg 3, SYLMAR CA: 91342-3853 <BR>Tel: 1 818 8335000 <BR>Fax: 1 818 8335067 <BR>Website: http://www.secondsight.com/

Read More

Who are in the management team of Vivani Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Vivani Medical, Inc. includes Chairman Gregg Williams, Acting CEO and Director Matthew Pfeffer, Director Jonathan McGuire, and Independent Director Aaron Mendelsohn. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Vivani Medical, Inc. includes the following individuals:<BR><BR>- Mr. Gregg Williams, who serves as the Chairman of the Board.<BR>- Mr. Matthew Pfeffer, who is the Acting Chief Executive Officer and also a Director.<BR>- Mr. Jonathan McGuire, who holds the position of Director.<BR>- Mr. Aaron Mendelsohn, who is an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Vivani Medical, Inc. overvalued or undervalued?

25-Jun-2025

Vivani Medical, Inc. is currently overvalued and has moved from a risky to a "does not qualify" valuation grade due to poor financial health, reflected in unfavorable metrics compared to peers and significant declines in return performance relative to the S&P 500.

As of 13 August 2020, Vivani Medical, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently overvalued, as evidenced by its Price to Book Value of 5.86, an EV to EBIT of -2.26, and an EV to EBITDA of -2.30, all of which reflect poor operational performance and financial instability.<BR><BR>In comparison to its peers, Vivani Medical's valuation metrics are unfavorable. For instance, Cardiff Oncology, Inc. has a P/E ratio of -5.0384 and an EV to EBITDA of -3.2378, while Pro-Dex, Inc. stands out with a very attractive P/E of 15.6736 and an EV to EBITDA of 11.4415. Additionally, Vivani Medical's return performance has lagged significantly behind the S&P 500 over the past three and five years, with declines of 81.5% and 60.75%, respectively, further reinforcing the notion that the company is overvalued in its current state.

Read More

Is Vivani Medical, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Vivani Medical, Inc. shows a neutral trend with mixed signals, being mildly bearish on the weekly MACD but bullish on the monthly, while outperforming the S&P 500 in the short term but underperforming over the longer three- and five-year periods.

As of 10 September 2025, the technical trend for Vivani Medical, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different indicators. The MACD shows a mildly bearish trend on the weekly chart, while it is mildly bullish on the monthly chart. The Bollinger Bands indicate a bullish stance on both weekly and monthly time frames. Daily moving averages are bullish, but the KST and OBV are mildly bearish on the weekly and show no trend on the monthly. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week (22.50% vs. 1.05%) and month (18.55% vs. 2.33%), but it has significantly underperformed over the longer terms, particularly in the 3-year and 5-year periods.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 76 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.11

stock-summary
Return on Equity

-520.10%

stock-summary
Price to Book

15.44

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.55%
0%
21.55%
6 Months
23.68%
0%
23.68%
1 Year
0%
0%
0.0%
2 Years
47.43%
0%
47.43%
3 Years
2.17%
0%
2.17%
4 Years
-73.89%
0%
-73.89%
5 Years
-65.19%
0%
-65.19%

Vivani Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Vivani Medical, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Vivani Medical, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different indicators. The MACD shows a mildly bearish trend on the weekly chart, while it is mildly bullish on the monthly chart. The Bollinger Bands indicate a bullish stance on both weekly and monthly time frames. Daily moving averages are bullish, but the KST and OBV are mildly bearish on the weekly and show no trend on the monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week (22.50% vs. 1.05%) and month (18.55% vs. 2.33%), but it has significantly underperformed over the longer terms, particularly in the 3-year and 5-year periods....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-50.41%
EBIT Growth (5y)
-1.05%
EBIT to Interest (avg)
-21.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.91%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.86
EV to EBIT
-2.26
EV to EBITDA
-2.30
EV to Capital Employed
56.53
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2500.70%
ROE (Latest)
-204.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.62%)

Foreign Institutions

Held by 7 Foreign Institutions (2.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -31.48% vs 16.92% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-5.60",
          "chgp": "-32.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.10",
          "val2": "-5.40",
          "chgp": "-31.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.56% vs -84.89% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.30",
          "val2": "-26.60",
          "chgp": "8.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.50",
          "val2": "-25.70",
          "chgp": "8.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.40
-5.60
-32.14%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.10
-5.40
-31.48%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -31.48% vs 16.92% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-24.30
-26.60
8.65%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.50
-25.70
8.56%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.56% vs -84.89% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Vivani Medical, Inc. stock-summary
stock-summary
Vivani Medical, Inc.
Pharmaceuticals & Biotechnology
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
Company Coordinates stock-summary
Company Details
12744 San Fernando Rd Bldg 3 , SYLMAR CA : 91342-3853
stock-summary
Tel: 1 818 8335000
stock-summary
http://www.secondsight.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."